Here we identify indirubin and its analogues as potent inhibitors of cyclin-dependent kinases (CDKs). The crystal structure of CDK2 in complex with indirubin derivatives shows that indirubin ...

Pfizer’s next-generation, highly selective CDK2 and CDK4 inhibitors are designed to be more specific and potent than currently approved CDK inhibitors. By directly and concurrently targeting ...

BeiGene has acquired an exclusive global licence to an oral cyclin-dependent kinase-2 (CDK2) inhibitor to treat breast cancer from Boston-based Ensem Therapeutics. As part of the agreement ...

In September, Incyte presented late-breaking Phase 3 results for retifanlimab (Zynyz ®) and initial data from the Phase 1 ...

A TYK Medicines Inc. patent discloses tricyclic compounds acting as CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer. BioWorld Science Cancer Patents Popular Stories ...

04, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and ...

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...

During the quarter, we also provided important clinical updates at ESMO with encouraging data for our CDK2 inhibitor in ovarian and endometrial cancer as well as data from the Phase 3 trial of ...